Neurodegeneration
Ances Bioimaging Laboratory
Beau M. Ances, MD, PhD
Developing advanced neuroimaging biomarkers to study aging and neurodegeneration. By combining MRI, PET, psychometrics, fluid biomarkers and microbiome data, the lab investigates diseases like Alzheimer’s, Down syndrome and neuroCOVID to improve diagnosis and guide therapies.
Bateman Lab
Randall Bateman, MD
Focused on understanding the pathophysiology of Alzheimer’s disease and related neurodegenerative disorders through advanced biomarker research and clinical studies. The lab specializes in developing and validating fluid biomarkers, conducting longitudinal studies and applying innovative techniques such as stable isotope labeling kinetics to measure protein dynamics. Its mission is to accelerate early diagnosis, improve therapeutic strategies and contribute to global efforts in Alzheimer’s research through collaboration and education.
Belloy Lab
Michael Belloy, PhD
Investigating the genetics of Alzheimer’s disease using a multi-modal approach that integrates genomics, imaging and clinical data to identify risk variants and inform drug development.
Cross Lab
Anne Cross, MD
Investigating the immunological processes underlying multiple sclerosis and related neuroinflammatory disorders. The lab focuses on understanding how immune cells interact with the central nervous system, identifying biomarkers of disease activity and developing strategies to prevent or reverse neurodegeneration. Its research integrates clinical observations with experimental models to advance therapeutic approaches and improve patient outcomes.
Davis Lab
Albert (Gus) Davis, MD
Investigating the molecular and cellular mechanisms behind alpha-synuclein aggregation in Parkinson’s disease and dementia with Lewy bodies. Using in vitro, cell culture and in vivo models, the lab aims to uncover how toxic protein forms drive neurodegeneration and to develop better diagnostics and treatments for synucleinopathies.
Fluid Biomarker Core
Suzanne E. Schindler, MD, PhD
The Fluid Biomarker Core has studied Alzheimer disease from multiple angles for more than 20 years. Currently the lab focuses on fluid biomarkers of disease with a particular interest in identifying individuals with preclinical and early stage AD. Our laboratory uses enzyme-linked immunosorbent assays (ELISA), bead-based immunoassays, single-molecule counting systems and automated immunoassays to study protein biomarkers in cerebrospinal fluid and plasma.
Gallardo Lab
Gilbert Gallardo, PhD
Investigates how reactive astrocytes and neuroinflammation contribute to neurodegenerative diseases like Alzheimer’s. Using biochemistry, molecular biology, cellular inflammation models and mouse studies, the lab aims to uncover mechanisms of astrocyte-driven neurotoxicity and develop therapies that target these pathways to reduce brain inflammation.
Geisler Lab
Stefanie Geisler, MD
Investigating the molecular mechanisms behind peripheral neuropathy to develop effective treatments. Using both clinical and experimental models, the lab focuses on axon degeneration, neuron-glia interactions and chemotherapy-induced neuropathy to improve patient outcomes and quality of life.
Holtzman Lab
David Holtzman, MD
Leading research into the mechanisms of neurodegeneration, with a focus on Alzheimer’s disease. Through studies on proteins like apoE and tau, and factors such as sleep, immune response and neuronal activity, the lab aims to uncover pathways that drive disease progression and identify targets for therapy.
Hyrc Lab
Krzysztof Hyrc, PhD
Studies ionic mechanisms of excitotoxic neuronal cell death. Using optical techniques and low affinity calcium indicators, the lab investigates intracellular ion concentrations to better understand how neurons respond to injury and stress.